![]() Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines. | ![]() Catalent Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. | ![]() Bristol Myers Squibb Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products. | ![]() Idorsia Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. | ![]() Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. | ![]() Sanofi Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. | Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. | ||
Founding Date | Founding Date 1988 | Founding Date 2003 | Founding Date 2007 | Founding Date 1887 | Founding Date 2017 | Founding Date 1980 | Founding Date 2004 | Founding Date 1978 |
Type | Type Public | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||
Locations | Locations Tarrytown, US HQ Mississauga, CA Courbevoie, FR München, DE Bengaluru, IN Dublin, IE Limerick, IE see more | Locations Menlo Park, US HQ | Locations Somerset, US HQ Buenos Aires, AR Bruxelles, BE Charleroi, BE Charleroi, BE Charleroi, BE Indaiatuba, BR see more | Locations Princeton, US HQ Mulgrave, AU Pinewood, AU Wien, AT Braine L'alleud, BE Bruxelles, BE São Paulo, BR see more | Locations Allschwil, CH HQ Shanghai, CN Lörrach, DE Chiyoda City, JP | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | |
Employees | Employees 13,9264% increase | Employees 4337% increase | Employees 16,9005% decrease | Employees 34,1001% decrease | Employees 8007% increase | Employees 25,200 | Employees 86,088 | Employees 7,57013% decrease |
Valuation ($) | Valuation ($) 102.2 b | Valuation ($) N/A | Valuation ($) 10.7 b | Valuation ($) 97.8 b | Valuation ($) N/A | Valuation ($) 170.4 b | Valuation ($) 141.1 b | Valuation ($) 26.7 b |
Financial | ||||||||
Revenue (est.) | Revenue (est.) $13.1b (FY, 2023) | Revenue (est.) $106.7m (FY, 2021) | Revenue (est.) $4.4b (FY, 2024) | Revenue (est.) $45b (FY, 2023) | Revenue (est.) CHF152.4m (FY, 2023) | Revenue (est.) $28.2b (FY, 2023) | Revenue (est.) €43.1b (FY, 2023) | Revenue (est.) $9.8b (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods $30m (FY, 2021) | Cost of goods $3.4b (FY, 2024) | Cost of goods $10.7b (FY, 2023) | Cost of goods CHF7.2m (FY, 2023) | Cost of goods $8.5b (FY, 2023) | Cost of goods €12.5b (FY, 2023) | Cost of goods $2.5b (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit $76.7m (FY, 2021) | Gross profit $953m (FY, 2024) | Gross profit $34.3b (FY, 2023) | Gross profit CHF146.4m (FY, 2023) | Gross profit $19.7b (FY, 2023) | Gross profit €34.5b (FY, 2023) | Gross profit $7.3b (FY, 2023) |
Net income | Net income $4b (FY, 2023) | Net income ($159.6m) (FY, 2021) | Net income ($1b) (FY, 2024) | Net income $8b (FY, 2023) | Net income (CHF297.9m) (FY, 2023) | Net income $6.7b (FY, 2023) | Net income €5.6b (FY, 2023) | Net income $1.2b (FY, 2023) |
Operating ⚠ | ||||||||
Countries | Countries N/A | Countries N/A | Countries 80 (FY, 2023) | Countries N/A | Countries N/A | Countries 100 (FY, 2020) | Countries N/A | Countries N/A |
Facilities | Facilities N/A | Facilities 1 (FY, 2016) | Facilities N/A | Facilities N/A | Facilities N/A | Facilities 180 (FY, 2020) | Facilities N/A | Facilities N/A |
Patents (EU) | Patents (EU) 17 (FY, 2020) | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) 21 (FY, 2020) | Patents (EU) N/A | Patents (EU) N/A |
Patents (US) | Patents (US) 31 (FY, 2020) | Patents (US) 30 (FY, 2016) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 31 (FY, 2020) | Patents (US) N/A | Patents (US) 21 (FY, 2021) |
Patents Issued | Patents Issued N/A | Patents Issued 77 (FY, 2016) | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued 34 (FY, 2021) |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 20 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products 10 (Q2, 2022) |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 20 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 9 (FY, 2021) | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 5 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products 8 (Q2, 2022) |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 15 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 12 (FY, 2021) | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products 9 (Q2, 2022) |
Products | Products 11 (FY, 2022) | Products 2 (FY, 2016) | Products 8 k (FY, 2023) | Products N/A | Products N/A | Products N/A | Products N/A | Products N/A |
Projects in R&D Pipeline | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 12 (FY, 2019) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 91 (FY, 2019) | Projects in R&D Pipeline N/A |
Trademarks | Trademarks 20 (FY, 2022) | Trademarks 29 (FY, 2016) | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A |
Funding | ||||||||
Total funding raised | Total funding raised $ 53.9m | Total funding raised $ 102.9m | Total funding raised $ 650m | Total funding raised $ 15.5m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 310m | Total funding raised N/A |
Intersect ENT is an ear, nose, and throat medical technology company.
View companyCatalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products.
View companyBristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products.
View companyIdorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs.
View company